Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment ...

Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to trac ...

Q2 2025 Earnings Call Transcript August 6, 2025 Fortrea Holdings Inc. beats earnings expectations. Reported EPS is $0.19, ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding sharehol ...

THE Philippine Council for Health Research and Development (PCHRD) is seeking stronger alignment between health research and policymaking as it hosts the 18th Philippine National Health Research ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Clearway ...

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Net loss (GAAP) increased by $5,600,000 to $16,600,000 for the fiscal third quarter ended June 30, 2025, reflecting a ...

Q2 2025 Pre Recorded Earnings Conference Call August 7, 2025 2:00 AM ETCompany ParticipantsKhalid Waleed Hosny ...